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Forward genetic screensThe elucidation of the human and mouse genome sequence and developments in high-throughput genome
analysis, and in computational tools, have made it possible to proﬁle entire cancer genomes. In parallel with
these advances mouse models of cancer have evolved into a powerful tool for cancer gene discovery. Here we
discuss the approaches that may be used for cancer gene identiﬁcation in both human and mouse and discuss
how a cross-species ‘oncogenomics’ approach to cancer gene discovery represents a powerful strategy for
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Tumours form when a cell gains a selective advantage over other
cells and manages to evade the checkpoints that would normally
suppress its growth. The acquisition of this behaviour is thought to
occur as a result of the development of somatic mutations that
deregulate gene function. Somatic mutations in humans may result
from a multitude of genetic insults generating different types of
genetic lesions. With the exception of point mutations, these lesions
are rarely focal and often encompass many genes making the
identiﬁcation of the deregulated gene within the rearranged region
problematic. In this review we will discuss the technological
approaches that may be applied for ﬁnding cancer genes. An overview
of these technologies is provided in Table 1.
1.1. Gene resequencing
Advances in DNA sequencing technology have enabled the
identiﬁcation of recurrent intragenicmutations acrossmultiple cancer
genomes. Davies et al. [1] screened the coding sequence and intron–
exon junctions of BRAF for mutations in more than 900 human cancer
cell lines and primary tumours, and found somatic missense
mutations in 66% ofmalignantmelanomas and in a smaller proportion
of many other human cancers. 80% of BRAF-mutated melanomas were
found to contain a V600E substitution, which is thought to
constitutively activate the kinase by mimicking phosphorylation [1].
As the cost of sequencing has diminished, it has become possible to
perform larger scale screens to look for mutations in multiple genes
across multiple tumours. The ﬁrst large-scale systematic mutational
study of a complete gene family was performed by Bardelli et al. [2],
who identiﬁed 7 candidate cancer genes in a screen of the tyrosine
kinase gene family in 182 colorectal cancers. A further study of
mutations in the tyrosine phosphatase gene family identiﬁed 6
putative tumour suppressor genes that were mutated in 26% of the
colorectal cancers analysed [3]. Resequencing of the phosphatidyli-
nositol 3-kinase (PI3K) gene family revealed one member, PIK3CA,
which is frequently mutated in tumours of the colon, breast, brain and
lung, with most mutations clustering in the catalytic domain [4].
Mutations in PIK3CA have since been identiﬁed in additional tumour
types, such as hepatocellular carcinomas [5] and ovarian cancers [6,7].
A screen of serine/threonine kinases showed that 40% of colorectalTable 1
Overview of genomic technologies for cancer gene discovery.
Cancer gene discovery
approach
Resolution Pros
Gene resequencing Nucleotide Can be an accurate way of ﬁnding somatic mutatio
nucleotide level.
With new array-based sequence enrichment techn
entire exome can be proﬁled.
Expression analysis Transcript Expression data can be used for diagnostic and pro
purposes.
RNA-Seq based approaches can be used for proﬁlin
transcriptome including expression levels, splicing
gene discovery.
Comparative Genomic
Hybridization (CGH)
Megabase Large complex rearrangements can be discovered
technique.
Array-based Comparative
Genomic Hybridization
(aCGH)
100s bp High resolution. SNP-based platforms can report a
changes.
Sequencing entire
cancer genomes
Nucleotide Can report nucleotide level variation, copy number
and can also report neutral changes in the genome
balanced translocations and inversions.
Epigenetic proﬁling Nucleotide Can detect epigenetically silenced genes that would
other approaches.tumours harbour a mutation in 1 of 8 PI3K-pathway genes [8]. The
PI3K pathway regulates a wide range of cellular functions that are
important in cancer, including growth, proliferation, survival, angio-
genesis and migration [9].
Studies at the Wellcome Trust Sanger Institute have centred
round the resequencing of the coding regions of all 518 protein
kinase gene family members. A study of 25 breast cancers revealed
diverse patterns of mutation, with a variation in the number of
mutations and in the identity of mutated genes, such that no
commonly point-mutated kinase gene was identiﬁed [10]. A study of
33 lung cancers reached similar conclusions [11]. While both studies
showed an over-representation of nonsynonymous substitutions,
which would be predicted for “driver” mutations that confer a
selective growth advantage on the cancer cell, most of the mutations
were thought to be “passenger” mutations that were unlikely to
contribute to tumourigenesis. Protein kinase resequencing at the
Sanger Institute has culminated in the identiﬁcation of 921 base
substitution somatic mutations in 210 diverse human cancers types
[12]. Putative driver mutations were identiﬁed in 119 genes but 83%
of mutations were predicted to be passengers. Cancers showed
variation in mutation prevalence, with many of the cancer types with
highest prevalence originating from high turnover, surface epithelia
that are most exposed to mutagens [12]. Cancers also showed
different “mutational signatures”, which often reﬂect differences in
mutagenic exposure. For example, most lung cancers have a high
proportion of C:GNA:T transversions, which are caused by exposure
to tobacco carcinogens [11].
The ﬁrst study to approach the scale of a genome-wide screen
involved resequencing the coding regions of all (∼13,000) consensus
coding sequence (CCDS) genes in 11 breast and 11 colorectal cancers
[13]. Each cancer was found to harbour an average of 93 mutated
genes, of which at least 11 (189 candidates in total) were thought to be
driver mutations. Many of the functional groups and pathways
enriched for candidate cancer genes were unique to one or other
cancer type, suggesting differences in the tumourigenic process in
breast and colorectal cancers [14]. There have been claims that the
statistical analysis performed in this screen was ﬂawed, in part
because they used a different dataset to estimate background
mutation rates, which can vary between and within cancer genomes,
and because the sample size was small [15]. However, the ﬁndings of
this study are in agreement with those of Greenman et al. [12] inCons
ns at the PCR-based strategies are not readily scaleable to genome-wide and are
expensive.
ology the Array-based sequence enrichment is still developmental and many
protocols do not reproducibly capture the exome.
gnostic Because expression proﬁling is a quantitativemeasure of gene activity it
reports gene expression changes that are both the cause and the effect
of genetic and epigenetic changes at the DNA level which often makes
the output of these studies an ‘expression signature’ rather than a
cancer gene.
g the
and fusion
using this Largely outdated by array-based approaches. Not readily scaleable to
high-throughput.
Reveals large regions of rearrangement which may contain many genes
so ﬁnding causal rearrangements can be difﬁcult.
llele-speciﬁc Stromal contamination and immune cell inﬁltrates can inﬂuence the
ability of these platforms to determine the copy number of the cancer.
Like all genomics platforms array-based CGH reports to copy number
proﬁle of a population of cells so tumour heterogeneity can be an issue.
information
such as
Extremely expensive. Not clear how to computationally resolve highly
rearranged regions.
be missed by It has proved difﬁcult to develop technology to scale to genome-wide
epigenetic proﬁling at the nucleotide level.
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complex than previously thought [16]. The study has since been
expanded to include all of the human RefSeq [17] genes and a larger
number of breast and colorectal cancers [18]. 114 additional candidate
cancer genes were identiﬁed and most candidates were mutated in
fewer than 5% of tumours recapitulating the conclusions of previous
studies [12,13]. Each tumour was predicted to contain an average of 15
potential driver mutations, suggesting that each mutation makes only
a small contribution to tumourigenesis.
Although statistical methods can provide a prediction of the likely
driver and passenger mutations within a cancer, there is a strong
rationale for using functional assays to test these predictions. Frohling
et al. [19] resequenced the coding exons and splice junctions of the
receptor tyrosine kinase FLT3 in samples from patients with acute
myeloid leukaemia (AML). They found that out of 9 mutants with
candidate driver mutations, only 4 were able to transform cells in
culture (for a review, see [20]).
The Sanger Institute Catalogue of Somatic Mutations in Cancer
(COSMIC) collates and displays somatic mutation information relating
to human cancers [21]. At the time of writing (December 2008,
COSMIC release 40), the database contained mutation data for 4773
genes from 291,551 tumours. Gene resequencing is also a major
component of the $50 million 3-year pilot phase of the Cancer
Genome Atlas (http://cancergenome.nih.gov/), a large-scale colla-
boration between the National Cancer Institute (NCI) and the National
Human Genome Research Institute (NHGRI).
Gene resequencing studies have clearly been proven to be a fruitful
approach for candidate cancer gene discovery. Technological break-
throughs such as ‘exon-capture’ [22], where the entire exome can be
captured by array hybridization and sequenced on a parallel
sequencing platform, are likely to facilitate a dramatic increase in
genome-wide mutation data and will move large-scale gene rese-
quencing studies out of genome centres and place them within reach
of most research laboratories. Already this technology can be used to
capture the entire human exome and, with further improvements in
the reproducibility of this technology, it is likely to become the
method of choice for cancer mutation screens.
1.2. Gene expression proﬁling
Gene expression arrays can be used to analyse the transcription of
thousands of genes, or the entire transcriptome, simultaneously. There
are two main array-based gene expression platforms: cDNA arrays,
where clones corresponding to the transcripts to be analysed are
spotted onto a matrix, and oligonucleotide arrays, where oligonucleo-
tides corresponding to the transcripts are synthesised onto a matrix
along with mismatch control oligonucleotides. In two-colour micro-
array expression analysis, the sample of interest and a control sample
are differentially labelled with ﬂuorescent dyes and are hybridized
onto the array, which is then scanned to determine the ratio of
ﬂuorescence intensities for each gene. The ratio represents the relative
amounts of transcript in the sample. Unsupervised clustering of the
expression data for multiple samples can be used to subcategorise
cancers. For example, lung cancers cluster into known histological
subtypes, which are predictive of patient survival [23–25]. Gene
expression proﬁles may also provide an indication of the genes
involved in oncogenesis in a given tumour. Lung cancers harbouring a
mutation in KRAS have a characteristic expression proﬁle that can be
used in their identiﬁcation [26]. However, analysis of gene expression
rarely provides insights into the underlying genetic changes and it can
be confounded by physiological variation, such as the degree of
inﬂammatory response or hypoxia [27]. Nevertheless, it is important
as a complementary approach to other methods of cancer proﬁling,
such as mutational and copy number analysis. Integrative approaches
involving gene expression and copy number analysis are discussed in
the following section.Recently, a new approach for transcriptome analysis, called RNA-
Seq or transcript counting, was developed. This approach involves
sequencing the transcriptome of a cell or tumour on a parallel
sequencing platform. Gene expression levels are calculated by
‘transcript counting’. Because many millions of reads are generated
from each lane of a parallel sequencing run, RNA-Seq has a large
dynamic range. Early protocols for RNA-Seq involved generating short
(25–30 bp) sequence tags of the transcriptome. More recent protocols
involve the use of paired-end sequencing. Paired-end sequencing
greatly facilitates the generation of physical coverage of the
transcriptome and, as such, can be used to identify splice variants
and fusion transcripts. Because sequence data can be used for
nucleotide variant calling, RNA-Seq could potentially be used to
proﬁle a tumours' pattern of mutation. The other major advantage of
RNA-Seq is that it is not limited by the probes that can be tiled on an
array, and as such is a potent tool for transcript discovery. The RNA-
Seq approach and its application are reviewed in Wang et al. [28].
1.3. Analysis of DNA copy number changes
Changes in DNA copy number result from chromosomal aberra-
tions such as deletions and duplications, non-reciprocal transloca-
tions and gene ampliﬁcations. Copy number variants (CNVs) have
been identiﬁed in all humans studied [29], and a genome-wide study
of 270 apparently healthy individuals from four diverse populations
identiﬁed almost 1500 germline copy number variable regions
encompassing 12% of the human genome [30]. CNVs have been
reported to accounted for ∼18% of the total detected variation in gene
expression between individuals, suggesting that they make a
considerable contribution to phenotypic variation [31]. In the context
of cancer, genomic instability results in the acquisition of somatic
copy number aberrations that may contribute to tumourigenesis
through the ampliﬁcation of oncogenes and/or loss of tumour
suppressor genes.
Chromosomal instability, which may manifest as alterations in
chromosome number (aneuploidy) or inter- or intra-chromosomal
rearrangement, is thought to arise early in tumourigenesis but
increases with tumour progression (for a review, see [32]). There are
many mechanisms that underlie this transition and cells have evolved
potent checkpoints to eliminate cells with unstable genomes.
Fridlyand et al. [33] found that shorter or altered telomeres were
associated with a greater number of genomic ampliﬁcations and that
the frequency of low-level changes was associated with altered
expression of genes involved inmitosis, cell cycle, DNA replication and
repair. These included many genes that are direct targets of the
transcription factor E2F [33]. This has lead to the suggestion that the
Rb pathway plays an important role in regulating chromosomal
instability, as hypothesised by Hernando et al. [34,33]. Advanced
tumours tend to reach a stable state, which, in the form of cancer cell
lines, are stable over many generations and in different laboratories,
suggesting that they have evolved to an optimal state [35]. It has been
suggested that rather than a high level of chromosomal instability
promoting tumorigenesis, highly unstable cells are selectively
eliminated. This has lead to a ‘just right’ model of chromosomal
instability [36].
1.3.1. Using comparative genomic hybridization (CGH) to detect copy
number changes
Large alterations in copy number were initially detected and
quantiﬁed using metaphase spreads in a technique known as
comparative genomic hybridization (CGH) [37]. In CGH, cancer and
normal genomic DNA are differentially labelled with ﬂuorochromes
and are co-hybridized to normal metaphase chromosomes. Cot-1 DNA
is added to suppress hybridization to repetitive elements in the
genome. The ratio of ﬂuorescence intensities at any chromosomal
position is approximately proportional to the ratio of copy numbers of
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proﬁles can be viewed and compared using the NCBI Cancer
Chromosomes database, which integrates three databases of chromo-
somal aberrations in cancer: the SKY/M-FISH and CGH Database, the
Mitelman Database of Chromosome Aberrations in Cancer, and the
Recurrent Chromosome Aberrations in Cancer Database [39]. Rear-
rangement breakpoints are linked to the underlying genome
assembly. However, the tool is limited to cytogenetic resolution
because CGH cannot detect changes of less than 20 Mb or distinguish
changes that are close together, and cannot determine exact genomic
coordinates [38].
Array CGH is a higher resolution, high-throughput version of
conventional CGH, in which differentially labelled cancer and
reference samples are hybridized to an array made from large
genomic clones, e.g. bacterial artiﬁcial chromosomes (BACs), or
cDNAs (for reviews, see [38,40,41]). The copy number is measured
at each probe on the array, and can be mapped directly to the genome.
A disadvantage of array CGH is that it cannot detect LOH, which has
traditionally been identiﬁed using methods involving microsatellites
and restriction fragment length polymorphisms (RFLPs) that are not
suitable for large-scale analyses (see [42]).
Single nucleotide polymorphism (SNP) arrays are a more recent
development in copy number analysis. SNPs, which have been
reported to account for most of the genetic variation in the human
genome [31], occur on average every 100–300 base pairs along the
human genome sequence. The Affymetrix GeneChip Mapping Assay
(http://www.affymetrix.com) is a commonly used procedure that
combines awhole-genome sampling assay (WGSA)with high-density
SNP arrays [43,44]. WGSA is used to reduce the complexity of the
sample, and involves ligating a linker to restriction-digested DNA,
which enables PCR ampliﬁcation using a single primer that is
complementary to the adaptor. The ampliﬁed DNA is then fragmented,
labelled and hybridized to the array. SNPs within the ampliﬁed DNA
are used as probes on the array, therefore maximising the amount of
information that can be extracted from the experiment [45]. In the
Affymetrix GeneChip Mapping 10K Assay (which uses an array
containing 11,555 SNPs across the genome) WGSA involves a single
restriction enzyme, XbaI [43]. Regions of the genome in which the
XbaI site is rarewill be under-represented in the array [45]. The higher
resolution 100K SNP array therefore uses two restriction enzymes,
XbaI and HindIII, which produce complementary SNP densities [44].
Each SNP in an Affymetrix array is represented by a “probe set”
comprising multiple “probe quartets”. Each probe quartet consists of
four 25mer oligonucleotides in the form of two “probe pairs”
comprising a perfect match probe and a mismatch probe correspond-
ing to each SNP allele. Probe quartets differ from one another in offset,
i.e. the position of the polymorphic site relative to the centre of the
oligonucleotide, and orientation (reviewed in [46]). Normal and
tumour DNA are hybridized to different arrays, therefore avoiding the
need for matched samples and allowing for a pool of normal samples
to be used as a control. As in other forms of array CGH, the copy
number at each probe can be inferred from the intensity of
ﬂuorescence of hybridized sample DNA [45,47].
Commercially available arrays now range in resolution from10,000
to ∼1 million SNPs across the genome. SNP arrays therefore provide
the potential for ﬁne mapping of copy number changes, enabling the
identiﬁcation of small aberrations and accurate mapping of chromo-
somal breakpoints. Furthermore, the SNPs can be genotyped and
compared to a normal sample to identify regions of loss of
heterozygosity (LOH). This permits the identiﬁcation of complex
changes such as LOH without decrease in copy number and decrease
in copy number without LOH [45,47,48]. Such changes are common, as
demonstrated in pancreatic and cervical cancer cell lines, where the
proportion of LOH associated with copy-reduction was found to be
just 32% [49] and 25% [50], respectively. Allele-speciﬁc ampliﬁcation
can also be detected using SNP arrays.CGH signal intensities must be normalised to account for technical
bias while still retaining biologically relevant changes. Normalisation
of array CGH data has generally involved the use of methods originally
developed for normalising gene expression microarray data (for a
review, see [51]). Cross-slide and within-slide normalisation are used
to transform the data such that all arrays, and all the spots on each
array, are comparable. In median normalisation, all values are
multiplied by a constant factor so that all arrays have a median log2
ratio of 0. Lowess, or Loess, normalisation accounts for spot intensity
biases and other dependencies such as the location of the spot on the
array and the use of different print tips. The data are linearised by
subtracting a Lowess regression curve. A number of additional
methods for dealing with spatial effects in expression microarray
data are reviewed in Neuvial et al. [52].
In general, array CGH must be more stringent than gene
expression analysis because it is required to detect single copy
changes and, while the copy number of a gene, unlike the expression
level, is expected to be identical in two samples, this is often not the
case due to tumour heterogeneity and the presence of contaminating
stromal cells [53]. Khojasteh et al. [53] proposed a multi-step
normalisation process speciﬁcally for dealing with array CGH data. A
“spatial segmentation” algorithm has also been developed to account
for array CGH-speciﬁc spatial effects designated “local spatial biases”,
where clusters of spots show a shift in signal, and “continuous
spatial gradient”, where there is a smooth gradient in signal across
the array [52]. Staaf et al. [54] showed that copy number imbalances
correlate with intensity in array CGH data and that normalisation of
expression data erroneously corrects for biologically relevant gains in
copy number. They have therefore developed a normalisation
algorithm that prevents suppression of copy number ratios by
stratifying the data into separate populations representing discrete
copy number levels [54]. Array CGH data are also affected by a
genome-wide technical artefact termed “spatial autocorrelation”, or
“wave”, for which the peaks and troughs are aligned across samples
but the amplitude, and for some samples, the direction, varies [55].
Removal of the wave using a Lowess curve led to an increase in the
number of biologically relevant CNVs detected in array CGH data
from normal individuals [55].
Affymetrix has developed a number of procedures for normal-
ising SNP array CGH data. As described above, each SNP on an
Affymetrix array is represented by a probe set comprising multiple
probe pairs. Fluorescence on the mismatch probes represents non-
speciﬁc hybridization, and the data can be corrected by subtracting
the mismatch from the perfect match intensity for each probe pair.
The corrected intensities are then averaged across the probe set. The
data can be globally normalised by multiplying the average intensity
of the experimental array, i.e. the array to which the cancer sample is
hybridized, by a normalisation factor to make it numerically
equivalent to the average intensity of the control array, to which a
normal sample is hybridized. Intensity ratios are calculated by
dividing the average intensity for each SNP in the experimental array
by the equivalent value in the control array. Three software packages
that are commonly used for processing copy number data on
Affymetrix SNP arrays are Copy Number Analyser for GeneChip
arrays (CNAG) [CNAG, 56], DNA-Chip Analyzer (dChip) [dChip, 47]
and Affymetrix GeneChip Chromosome Copy Number Analysis Tool
(CNAT) (CNAT, [57]). These are compared and reviewed in Baross et
al. [58], who concluded that the detection of all real CNVs from a
100K array necessitated the combined use of multiple procedures.
The CNAG tool corrects for inter-experimental variation in PCR
kinetics by compensating for differences in the length of PCR
fragments and GC content, and uses the average of at least 5 “best-
ﬁt” normal samples that show the least variation between arrays as a
control [56]. A recently published algorithm, ITALICS, addresses the
problems of PCR kinetics plus additional sources of nonrelevant
variation between the probe quartet intensities, such as systematic
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approach to estimate and remove the nonrelevant effects from the
estimated biological signal [59].
ITALICS uses the GLAD algorithm [60] to estimate the biological
signal by inferring the copy number across the genome [59]. GLAD is
one of many methods that have been developed for segmenting the
genome into regions of homogeneous copy number. Different
approaches have been used, including change-point analysis, where
the genome is segmented at points in the genome where the copy
number changes signiﬁcantly [61,62], Hidden Markov Models
(HMMs) [56,63–67], hierarchical clustering along chromosomes [68]
and smoothing methods [69,70]. There are also a number of web-
based applications, such as ADaCGH [71] and CGHweb [72], for
viewing and comparing outputs from multiple algorithms. Further
methods have been developed to identify copy number changes
speciﬁcally in SNP array CGH data, which has increased noise at the
probe level compared with BAC array CGH [73], and a number of these
infer allele-speciﬁc copy numbers [56,73–76].
Finally, having identiﬁed regions of copy number change, the
statistical power can be increased by examining the region across
many samples. Unlike for CNVs in normal samples, cross-sample
analysis of copy number changes in cancer is hampered by the large
size of many rearrangements, variation in the location of breakpoints
between samples, and sample heterogeneity that prevents accurate
estimation of the copy number [55]. A handful of methods have been
developed to identify recurrent regions of copy number change in
tumours: CMAR [77], STAC [78], H-HMM [79] and KC-SMART [80]. The
latter is the only algorithm that does not discretise the data into 3
states (1, 0,−1), which can lead to undetected copy number changes
in heterogeneous tumours, and it enables the analysis of both large
and small aberrations [80].
1.3.2. Analysis of copy number changes in cancer genomes
CGH can detect aneuploidy, gene ampliﬁcations and deletions, and
non-reciprocal translocations in cancer genomes. Gene ampliﬁcations
are gains in copy number of restricted regions of DNA [81] that
contribute to tumourigenesis by increasing the transcript levels, and
therefore the protein levels, of oncogenes [82]. Gene ampliﬁcation is
the major mechanism of oncogenesis for a number of cancer genes,
including MYCN, which is ampliﬁed in ∼30% of advanced neuroblas-
tomas [83]. Ampliﬁed genes represent a promising target for cancer
therapy, as demonstrated in breast cancers harbouring an ampliﬁed
HER/ERBB2 receptor [84].
Deletions are an important mechanism for inactivating tumour
suppressor genes, including PTEN [85] and CDKN2A (INK4A/ARF) [86].
A genome-wide analysis of homozygous deletions in over 600 cancer
cell lines showed that deletions occur in regions with fewer genes and
repeat elements but higher ﬂexibility compared with the rest of the
genome [87]. A signiﬁcant proportion occur in regions that are prone
to chromosome breakage, and some of the genes in these “fragile
sites”, such as WWOX and FHIT, show similar mutational patterns to
known tumour suppressor genes, so it is not clear whether or not
these genes are causally implicated in cancer [88].
Like gene expression analysis, copy number proﬁling can be used
to subcategorise cancers. It can distinguish three subtypes of
glioblastoma [89], and separates leiomyosarcomas into a distinct
cluster from gastrointestinal stromal tumours, which, until recently,
were classiﬁed as the same tumour type [90]. It also provides
predictive power in breast cancer prognosis, where a poor prognosis
is indicated by high-level ampliﬁcation [91], extensive chromosome
instability [33] and/or the presence of multiple, closely spaced
amplicons, or “ﬁrestorms”, on a single chromosome arm [92]. Copy
number proﬁles can also help to stage a tumour, such as in cervical
cancer, where gain of chromosome 3q is associated with the
transition from severe dysplasia to invasive carcinoma [93].
Furthermore, studies in ovarian cancer have revealed an associationbetween drug response and the presence of copy number changes
associated with drug sensitivity or resistance [94,95]. The ampliﬁca-
tion of genes involved in drug metabolism or inactivation is
commonly observed in cultured cells as a means of acquiring drug
resistance [32].
While many cancer genomes have been analysed for copy number
changes, there has been limited progress in identifying the functional
signiﬁcance of altered regions. One successful approach involves
identifying recurrently altered regions that are speciﬁc to particular
tumour types. This enables the identiﬁcation of “lineage addiction”
cancer genes, which may target essential lineage-speciﬁc survival
functions and therefore represent promising therapeutic targets [96].
Two such genes are the melanoma-speciﬁc oncogene MITF, which is
selectively ampliﬁed and overexpressed in 20% of melanomas [97],
and NKX2-1, which lies in the minimal ampliﬁed region of a lung-
cancer-speciﬁc 14q13.3 amplicon found in up to 20% of lung cancers
[98,99]. Genes TTF1 and NKX2-8 are usually co-ampliﬁed with NKX2-1
in the 14q13.3 amplicon and all three genes have been shown to co-
operate in lung tumourigenesis [99]. The co-occurrence and mutual
exclusivity of copy number alterations at different loci may also reﬂect
co-operating and complementary cancer genes, respectively. For
example, gains of ERBB2 and CCNE1 frequently co-occur in bladder
cancer, while CCND1 and E2F1, which function in the same pathway,
never co-occur [100].
The identiﬁcation of cancer genes in regions of copy number
change can be challenging because changes often span large regions of
the genome that encompass many genes and may include many
attractive candidates. Gains of more than one copy may have involved
multiple evolutionary events and the critical gene may reside at the
highest peak in copy number, as demonstrated for oncogenes CYP24
and ZNF217 in breast cancer [101]. Measurement of gene expression is
also important for evaluating candidate cancer genes. SPANXB was
identiﬁed as the putative critical gene in an Xq duplication in acute
lymphoblastic leukaemias with an ETV6/RUNX1 translocation as a
result of high and uniform overexpression across all samples [102].
While gene expression and gene dosage are rarely perfectly
correlated, many studies, such as the comparison of array CGH and
gene expression data in breast cancers, have shown good correlation
[103,104]. However, genes that are ampliﬁed are not necessarily
overexpressed, as demonstrated by Kloth et al. [50], who did not
observe a genome-wide correlation between copy number and gene
expression in cervical cancer cell lines. Gene expression is inﬂuenced
by factors other than gene dosage, such as the availability of
transcription and regulatory factors, DNA methylation and chromatin
conformation, and the presence of miRNAs [50].
The integration of copy number analysis with gene resequencing
also facilitates cancer gene identiﬁcation. Mullighan et al. [105]
performed a genome-wide analysis of genetic alterations in 242
paediatric acute lymphoblastic leukaemias (ALL) using 100K and 250K
SNP arrays. They found mutations in genes that regulate late B
lymphocyte development in 40% of B-progenitor ALL cases. PAX5
mutations, which included deletions, point mutations and transloca-
tions, were identiﬁed in 32% of cases [105]. ALL genomes are relatively
stable, but genomes harbouring different translocations show varia-
bility in the number of copy number changes, which may reﬂect
differences in the number of events required for tumourigenesis
[105,106]. The integration of resequencing data, and epigenetic data,
can facilitate the identiﬁcation of tumour suppressor genes in regions
of LOH, where the other allele may be inactivated by point mutation or
epigenetic changes.
The identiﬁcation of human cancer genes is aided by the
integration of a number of complementary genome-wide analyses of
human cancers, but the integration of cancer-associated mutation
datasets from other species, particularly the mouse, provides an even
more powerful approach for cancer gene discovery. Cross-species
cancer gene analysis is discussed in Section 3.
Fig. 1. End-sequence proﬁling of tumour DNA. The tumour genome is fragmented and
the ends of the fragmented DNA molecules are sequenced. These sequenced ends are
then mapped to the reference genome. Ends that are an abnormal distance apart, or in
an abnormal orientation, shown here as “invalid”, are indicative of rearrangements
within the tumour genome. Redrawn with modiﬁcations from Raphael et al. [117].
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Limitations of CGH-based approaches include the inability to
determine the ploidy of the sample or to identify the location of
rearranged sequences in the cancer genome. However, the ploidy and
location of larger rearrangements (N10 Mb) can be discerned by
combining CGH with G-banding or Spectral Karyotyping (SKY) [107].
CGH may also struggle to detect low-level changes and changes in
heterogeneous samples, e.g. primary cancers containing normal
stromal cells, and it is affected by low-copy reiterated sequences,
including gene paralogues (for a full review, see [108]).
A further limitation of CGH is that while it can detect non-
reciprocal, or unbalanced, translocations, which result in the gain or
loss of DNA and often cause the inactivation of tumour suppressor
genes [109], it cannot detect reciprocal, or balanced, translocations.
These result in fusion transcripts or transcriptional deregulation due
to the positioning of an intact gene next to the promoter or enhancer
elements of another gene. Until recently, it was thought that balanced
translocations predominated in haematopoietic tumours, but an
assessment of data in the Mitelman Database of Chromosome
Aberrations in Cancer suggests that they also play an important role
in epithelial tumourigenesis [109]. Furthermore, human solid tumours
appear to contain large numbers of gene fusions [110] and a quarter of
the breakpoints detected in 3 breast cancer cell lines were found to be
balanced [111].
Balanced translocations are often initiating events in tumourigen-
esis that are essential for tumour development, and they therefore
represent promising therapeutic targets. However, the high-through-
put identiﬁcation of balanced translocations has been hindered
because translocation breakpoints cannot be ampliﬁed by PCR [111].
Genome-wide techniques for identifying translocations include array
painting, in which chromosomes are sorted and DNA is ampliﬁed and
hybridized to DNA microarrays [111], and informatics approaches,
such as the algorithm developed by Tomlins et al. [112] that used RNA
expression data to identify candidate gene fusions in prostate cancers.
The EML4-ALK fusion was identiﬁed in non-small-cell lung cancers by
paired-end sequencing [113].
End-sequence proﬁling (ESP) can be used to precisely map all
types of genomic rearrangements, including balanced translocations
[114] (Fig. 1). ESP involves constructing a BAC library from the cancer
genome and sequencing the ends of clones to identify rearrange-
ments, which map to locations in the reference genome that are of
abnormal distance or orientation [114]. DNA may also be sheared and
end-sequenced on a parallel sequencing platform [115]. The method
can also identify fusion transcripts (tESP) and can be targeted to
speciﬁc amplicons [110]. Complete sequencing of the BACs enables
detailed analysis of the structure of genomic rearrangements,
enabling elucidation of the mechanisms of rearrangement. ESP-
based analysis of 4 cancer amplicons revealed evidence for sister
chromatid break–fusion–bridge cycles, the excision and reintegration
of double minutes (extrachromosomal DNA), and more complex
architectures involving clusters of small genomic fragments [81].
Break–fusion–bridge cycles are initiated by a double-strand chromo-
somal break, which, following DNA synthesis, results in sister
chromatids with identical free DNA ends that fuse to one another to
prevent apoptosis. An anaphase bridge is formed during chromatid
separation in mitosis, and this results in a new double-strand break
and reinitiation of the cycle [116].
ESP analysis of 6 epithelial cancers, including primary tumours
from brain, breast and ovary, plus a metastatic prostate tumour and 2
breast cancer cell lines, revealed extensive chromosomal rearrange-
ments, some of which appeared to be recurrent [117]. However, ESP is
not suitable for analysing large numbers of cancer genomes. A high-
throughput approach, which involvesmassively parallel sequencing of
the ends of randomly sheared DNA, has recently been applied to the
genome-wide analysis of somatic and germline rearrangements in 2
lung cancers [115]. The analysis revealed a wide spectrum ofrearrangements, as well as providing high-resolution copy number
information. Despite the beneﬁts of this strategy, sequencing large
numbers of clones across many cancer genomes is costly and
impractical. However, Bashir et al. [118] have derived a formula to
maximise the probability of detecting fusion genes with the least
amount of sequencing. The formula depends on the distribution of
gene lengths and the parameters of the sequencing strategy used
[118]. Paired-end sequencing is an attractive strategy for the complete
characterisation of rearrangements in cancer. However, the recent
discovery that cytogenetically balanced translocations are frequently
associated with focal copy number alterations suggests that high-
resolution array CGH may in fact be suitable for detecting most
translocations in cancer [107].
1.4. Sequencing whole cancer genomes
With the advent of new sequencing technologies it is now
possible to screen the cancer genome for rearrangements [115] and
to sequence entire genomes [119,120]. This technology has rapidly
been applied to the study of the cancer genome [121]. The ﬁrst
cancer genome to be sequenced was that of an acute myeloid
leukaemia with a normal karyotype [121]. This study identiﬁed
mutations in a number of previously known cancer genes and
several mutations in novel genes, which were investigated in a larger
set of acute myeloid leukaemias ﬁnding that many of these
mutations were unique to the sequenced cancer. The short read
technology used in these human genome sequencing projects is
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variant calling in the non-repetitive regions of the genome, but
resolving entire genomes to the quality of the human genome
assembly is not possible with this technology due to the repetitive
nature of the human genome and the signiﬁcant level of rearrange-
ment normally found in human cancers. To completely sequence an
entire cancer genome, application of some of the new experimental
long read sequencing technologies will need to be achieved. The
other confounding factor in the analysis of tumours is that they
exhibit signiﬁcant molecular heterogeneity adding to the complexity
of deciphering the cancer genome and making cancer genome
sequencing a signiﬁcantly more complex undertaking than sequen-
cing genomes to assess germline variation. Despite these difﬁculties,
sequencing whole cancer genomes is clearly a major advance from
which we will learn a signiﬁcant amount about the genes involved in
cancer formation and how the cancer genome evolves. Recently, the
International Cancer Genome Consortium was formed to co-ordinate
the sequencing of human cancer genomes. This ambitious project
will sequence the genomes of all of the major cancer types and will
undoubtedly precipitate a revolution in how we think about cancer
and the genes that drive its development.
1.5. Epigenetic proﬁling
Epigenetic changes are chemical modiﬁcations to the DNA or
histones that change the structure of chromatin but do not alter the
DNA sequence. If chromatin is in the condensed conformation,
transcription factors cannot access the DNA and genes are therefore
not expressed, whereas genes in open chromatin can be expressed as
required. DNA methylation and changes in chromatin conformation
have both been implicated in tumourigenesis. DNA methylation of
CpG islands, which are located in promoter regions, can result in gene
“silencing” by preventing transcription factor binding. It can also
repress gene expression by recruiting methyl-binding domain
proteins, which associate with histone deacetylases (HDACs). HDACs
mediate chromatin condensation by deacetylating histones. [122].
Aberrant DNA methylation of CDKN2A has been observed in a
wide range of common cancer types [123,124], while VHL and BRCA1
are silenced by methylation in a signiﬁcant proportion of kidney
[125] and breast and ovarian cancers [126], respectively. VHL and
BRCA1 are also frequently mutated in cancer, but for other tumour
suppressor genes, such as RASSF1A, promoter hypermethylation
appears to be the principal mechanism for inactivation (for a review,
see [127]).
Methods involving high-density oligonucleotide arrays have been
developed for genome-wide detection of epigenetic changes. Detec-
tion of DNA methylation relies on the ability to distinguish cytosine
from 5-methylcytosine, while histone modiﬁcations can be detected
using chromatin immunopreciptation (ChIP). Large genomic regions,
such as an entire chromsome arm, can show aberrant methylation in
cancer [128], and there is evidence to suggest that some cancers
show a CpG island methylator phenotype (CIMP). CIMP+colorectal
cancers have signiﬁcantly more hypermethylation at CpG islands,
including an increased incidence of CDKN2A and THBS1 methylation
[129], and they are characterised by a methylated mismatch repair
gene, MLH1, which gives rise to microsatellite instability [130]. Genes
that are reversibly repressed by Polycomb proteins in embryonic
stem cells are signiﬁcantly over-represented amongst constitutively
hypermethylated genes in colorectal cancers [131]. This provides
support for the theory of a stem cell origin of cancer. A detailed
discussion of the epigenomics of cancer is beyond the scope of this
review, which focuses on changes in cancer that alter the DNA
sequence. Epigenomics approaches are reviewed in Callinan and
Feinberg [132] and, for a detailed review of epigenomics and its
relevance to the cancer stem cell hypothesis, see Jones and Baylin
[133].1.6. Insertional mutagenesis and cancer gene discovery in human
In the proceeding section of this review we will discuss the
application of mousemodels for cancer gene discovery, including how
insertional mutagenesis has been deployed to ﬁnd cancer genes. It is
important, however, to note that insertional mutagenesis is not
conﬁned to experimental organisms, and is a mechanism of cancer
initiation in humans.
There are several oncogenic viruses that afﬂict humans including
the human papilloma virus, the Human T-cell Lymphotropic Virus
(HTLV1), the hepatitis family of viruses, and the human immunode-
ﬁciency virus (HIV) that have all been implicated as insertional
mutagens. In each case, it has been shown that the virus may integrate
near cancer related genes, although whether clonal insertion events
occur is unclear [134–137]. Insertional mutagenesis in humans has
been proven to occur in patients who have received retroviral therapy
for SCID-X1. Some of these patients developed T-ALL after having
received an autologous transplant of cells transducedwith a retrovirus
expressing a wildtype copy of the γc gene, which is mutated in SCID-
X1. Several of these patients acquired clonal viral insertions upstream
of LMO2, implicating this gene as an oncogene [136]. Recently it was
suggested that transcriptional upregulation of LMO2 by retroviral
insertions alone was insufﬁcient for cancer to form, and that
alterations in other genes such as NOTCH1 were required [138].
1.7. Using pathways to predict cancer genes and their function
In this review,wehave largely focused on genediscovery by looking
for mutated, silenced, or rearranged genes. An alternative way of
discovering cancer genes is to build pathways around them and to
examine how they are ‘connected’ to each other and how they
participate in a biological process. This approach is called ‘network
modelling’. By combining gene expression data, functional genomic
data and proteomic data, components of the network can be linked.
This approach was shown to link breast cancer susceptibility to
centrosome dysfunction in tumours carrying BRCA1 mutations, and
importantly identiﬁed the HMMR gene as a new breast cancer
susceptibility gene [139]. An alternative approach is to develop
‘module maps’ which cluster genes together based on their behaviour
or expression. Recently it was shown that genes may be clustered
together to form an embryonic stem cell module map, and that
expression of genes that form this signature of ‘stemness’ is predictive
of decreased survival in both mouse and human cancers [140,141].
Similarly, genes may be implicated as possible cancer genes based on
their functional or physical interactionwith known cancer genes [142].
2. Cancer gene discovery in the mouse
2.1. The mouse as a model for studying cancer
Themouse is a leadingmodel system for cancer research because it
has a rapid reproduction rate, breeds well in captivity, and, owing to
its small size, can bemaintained in large numbers in limited space. It is
also genetically and physiologically similar to humans. Additionally,
the mouse genome has been sequenced and annotated to a high
standard, second only to that of human (see [143]).
The mouse was initially used for tumour transplantation within
inbred strains, but following the discovery of the immunodeﬁcient
“nude” mouse and, later, the severe combined immunodeﬁcient
(SCID) mouse, it became possible to transplant human tumours into
the mouse, creating xenograft models. Such models can be used to
rapidly assess tumour tissue and cell lines in vivo but they do not fully
recapitulate the behaviour of an endogenous tumour because many
features of the tumour microenvironment, such as stromal cells,
vasculature and immune cells, are missing. The tumour xenograft is
also likely to be less heterogeneous than the endogenous tumour
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factors have contributed to the limited success of xenograft models in
drug development (for a review, see [144]).
Many inbred strains that spontaneously develop cancer at high
frequency have been established, and these, as well as mice that have
been treated with a mutagen, are useful for studying the properties of
endogenous cancers in vivo. They have been used to identify cancer
genes and to assess the effects of carcinogens and therapeutic
compounds. However, these models may be biased towards speciﬁc
types of tumour that show variable penetrance and latency and that
do not accurately reﬂect common human cancers [143].
2.2. Genetically engineered mouse models
Genetically engineered mouse models represent a major advance
in cancer research that allows for the study of gene function in vivo
and for the creation of models that more accurately recapitulate
human cancers. Genetically engineered models can be classiﬁed as
transgenic or endogenous [143].
2.2.1. Transgenic models
Transgenicmice canbe created to study the effect of overexpressing
an oncogene or a dominant-negative tumour suppressor gene, which
encodes a mutant tumour suppressor that can inactivate the wildtype
protein. Transgenic mice can be generated by pronuclear microinjec-
tion, inwhich a construct containing the gene of interest (transgene) is
microinjected into the mouse oocyte after fertilisation and randomly
integrates into the genome, usually in tandem copies. If the transgenic
cells contribute to the germ line, the genetic change can be transmitted
to the next generation, producing mice that are fully transgenic and
establishing a strain. Many genes involved in cancer development are
also essential for mouse development. Therefore, to prevent embryo-
nic lethality and to restrict overexpression to speciﬁc tissues, the
construct containing the gene of interest also contains promoter
elements designed for spatial and temporal restriction of gene
expression. For example, the Tet-On and Tet-Off systems [145] promote
gene expression in the presence or absence of doxycycline, a non-toxic
analogue of tetracycline, while fusing the gene of interest to a gene
encoding the oestrogen receptor binding domain results in an inactive
protein that is activated upon treatment with Tamoxifen [146].
Limitationsof themicroinjectionmethod include thepossibility that,
because the transgene integrates randomly, it could disrupt other genes,
resulting in a phenotype that does not reﬂect the function of the gene of
interest (for a review, see [147]). In addition, the tendency of the
transgene to integrate in multiple copies could result in excessive
overexpression that is toxic to the animal [147]. However, transgenic
mice have made a signiﬁcant contribution to cancer research. In the
earliest examples, mouse models were used to demonstrate the role of
oncogenes in cancer. For example, tissue-speciﬁc overexpression of the
Myconcogene inmammaryglandsandB-cells resulted in the generation
of mice prone to breast cancer [148] and lymphomas [149], respectively.
Overexpression of dominant-negativemutant tumour suppressor genes
has also proved effective, e.g. type II transforming growth factor beta
(Tgfβ) receptor has been shown to accelerate chemically induced
tumourigenesis in the mammary gland and lung [150].
2.2.2. Targeted/endogenous models
A knockout mouse can be created to study the effect of inactivating
a tumour suppressor gene. In this method, a targeting vector is
transfected into embryonic stem (ES) cells, which are harvested from
the inner cell mass of mouse blastocysts. The vector must share
homologywith the region of themouse gene that is being targeted, i.e.
the tumour suppressor gene of interest, and must also contain genes
for selection, such that only cells inwhich the vector DNA has replaced
the endogenous DNA by homologous recombination will survive. The
surviving ES cells are injected back into a blastocyst, and willcontribute to all cell lineages, including the germ line [151]. The
targeting vector can be engineered to knock out the whole gene or
part of a gene, or small changes can be introduced into the gene
sequence. Alternatively, the complete gene under the control of a
strong promoter can be introduced to create a knockin mouse for
overexpressing oncogenes. By targeting a single copy to the genome,
this overcomes the problems associated with pronuclear microinjec-
tion (for a review, see [147]).
As with transgenic mice, mutations can be spatiotemporally
regulated. Conditional mousemodels frequently use the Cre–lox system
from bacteriophage P1, in which Cre recombinase catalyses recombina-
tion between loxP sites [152], and the intervening DNA is deleted or
inverted, depending on the orientation of the sites [153]. loxP sites can
therefore be placed on either side of a gene region to remove that region
in the presence of Cre. Large-scale chromosomal deletions and
inversions can also be generated by placing loxP sites, either in the
same orientation for deletions or the reverse orientation for inversions,
further apart on the chromosome [154,155], while chromosomal
translocations can be created by placing a loxP site at each breakpoint
[156] on non-homologous chromosomes. Conditional oncogene expres-
sion canbeachievedby insertinga stop cassette,which isﬂankedby loxP
sites, between the promoter and the ﬁrst exon such that Cre-mediated
excision of the cassette results in expression of the gene [157,158].
Unlike the conditional expression systems in transgenic mice, once
Cre recombinase has been expressed, the change is irreversible, and
there is evidence to suggest that Cre can be cytotoxic, perhaps due to
recombination at pseudo-loxP sites (see [159]). In addition, the Cre–
lox system cannot generate conditional point mutations, and this
represents a signiﬁcant limitation since point mutations and deletions
do not always produce the same phenotype [143]. However, the Cre–
lox system has proved invaluable in creating models that would
otherwise not arise or survive. For example, homozygous Brca1 and
Brca2 knockouts die early in embryogenesis, and heterozygous mice
are not tumour-prone, but mice harbouring a Cre-mediated deletion
of Brca1 [160] or Brca2 and Trp53 [161] in the adult mammary gland
do develop mammary tumours. Likewise, Trp53 mutations have been
identiﬁed inmany types of human cancer, but if Trp53 is mutated in all
cells, the mouse is most likely to develop lymphomas and sarcomas.
Conditional Trp53 mutations can be used to create models for human
cancers that are driven by Trp53 mutation in other tissues [159]. The
Flp/FRT system from Saccharomyces cerevisiae is an alternative to Cre–
lox that works in a similar way (see [159]).
2.3. Mouse models in cancer gene discovery
The methods described earlier in the review can also be applied to
the identiﬁcation of candidate cancer genes in the mouse. For
example, array CGH has been used to identify regions of copy number
change in mousemodels of malignant melanoma [162] and pancreatic
islet carcinomas [163]. However, as with human cancers, by the time
the cancer has presented, it is difﬁcult to distinguish the important
driver mutations from the background of passenger mutations.
The genetically engineered mouse models discussed thus far are
useful for studying the function of a particular gene or for represent-
ing a speciﬁc human cancer, but the tumours in these models do not
evolve naturally. In general, the initiating event, i.e. the engineered
mutation, is present throughout a tissue, whereas in natural
tumourigenesis, the tumour develops from one mutated cell. Like-
wise, in mouse models used to study the combined action of multiple
genes in cancer, the genes of interest are usually simultaneously
mutated, whereas “natural” tumours progress through a multi-step
process, where mutations are gradually acquired. Finally, manymouse
models are designed to show high penetrance and short latency to
keep costs down, but as a result they may not possess many of the co-
operating oncogenic events that would eventually be acquired by a
naturally evolving tumour (for reviews, see [143,144]).
Fig. 2. Structure of insertional mutagens used for cancer gene discovery in the mouse.
(A) The provirus contains two long terminal repeats (LTRs) ﬂanking the genes required
for viral assembly. Elements within the LTRs drive transcription of the viral genes but
can also inducemutation of nearby cellular genes. Splicing of a viral splice donor (SD) or
cryptic splice donor (not shown) to a splice acceptor or cryptic splice acceptor in the
ﬁrst intron or 5′ UTR of a cellular gene results in the formation of a chimeric transcript,
in which the celluar gene is coupled to the viral promoter. Splicing of a splice donor or
cryptic splice donor in a cellular gene to a viral splice acceptor (SA) or cryptic splice
acceptor (not shown) can cause premature termination of gene transcription owing to
the presence of polyadenylation signal (pA) and cryptic polyadenylation signals (not
shown) in the LTR. Adapted from ﬁgure in Uren et al. (see [164,168]). Figure is not to
scale. (B) Structure of the Sleeping Beauty transposon T2Onc [242]. The presence of
splice acceptors (SA) and polyadenylation signals (pA) in both orientations enables
premature termination of gene transcription from intragenic insertions in both
orientations. The transposon also contains the murine stem cell virus (MSCV) 5′ LTR
and a splice donor (SD) site that can induce promoter mutations in cellular genes.
Elements for mutagenesis are ﬂanked by 2 IR/DR elements, shown as arrows, which are
required for transposon mobilisation.
Fig. 3.Mechanisms ofmutagenesis by themurine leukaemia virus. The provirus is shown
in blue; coding and non-coding exons are shown in red and white, respectively. (A)
Enhancermutation. An enhancer element in the 5′ LTRofMuLV can cause upregulation of
nearby cellular genes. Oncogenic insertions of this type are most frequently found
upstream and in the antisense orientation with respect to the cellular gene(s) that they
are mutating. (B) Promoter mutation. Insertion of MuLV into the promoter region of a
cellular gene results in chimeric transcripts that are produced at higher levels than the
endogenous gene transcript. (C) Truncating mutation. Intragenic MuLV insertions can
cause premature termination of gene transcription, resulting in either gene upregulation
or gene inactivation. The ﬁgure shows an insertion within the 3′ UTR region, which may
remove mRNA-destabilising motifs, thereby stabilising the gene transcript.
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novel cancer genes reﬂect themutations found inhumancancers, and this
requires more accurate modelling of the natural evolution of tumours.
2.4. Forward genetic screens in the mouse
Forward genetic screens using somatic mutagens are a powerful
approach for cancer gene discovery in the mouse. Insertional
mutagens allow for relatively unbiased, genome-wide, identiﬁcation
of both novel cancer genes and collaborations between genes involved
in cancer. Chemical mutagenesis, using agents such as N-ethyl-N-
nitrosourea (ENU), is a highly efﬁcient way of inducing tumours in
mice but the causal mutations can be hard to identify. In contrast,
insertional mutagenesis using retroviruses and transposons is an
effective approach for inducing the stepwise progression of a cell to
malignancy, and for the identiﬁcation of the causal genetic lesions,
because the mutagen acts as a molecular ‘tag’ allowing its location in
the genome to be easily determined.
2.4.1. Retroviral insertional mutagenesis
2.4.1.1. Mechanisms of mutagenesis. The slow transforming retro-
virusesmurine leukaemia virus (MuLV) andmousemammary tumour
virus (MMTV) have been widely used for insertional mutagenesis in
the mouse. Unlike acute transforming retroviruses, which induce
tumours by expression of a viral oncogene, slow transforming
retroviruses do not carry an oncogene, and tumours are induced bymutations caused by insertion of the retrovirus into the host genome.
Consequently, tumours develop with a longer latency of 3–12 months,
compared with 2–3 months for acute transforming retroviruses [164].
MMTV was identiﬁed as a causative agent in several strains of mice
that were prone tomammary tumours, whileMuLVwas identiﬁed as a
causative agent in the lymphoma-prone AKR mice (see [165]).
Retroviruses infect host cells by binding of the viral envelope
proteins to cell surface receptors. Once the retrovirus has inserted into
the host genome, forming a provirus, it will produce viral envelope
proteins that occupy the cell surface receptors and prevent reinfection
of the same cell. However, recombination with endogenous viral
sequences results in the production of envelope proteins that bind to
other receptors. This, combined with the fact that many proviruses
have defective envelope coding sequences, enables retroviruses to
reinfect the same cell, resulting in the accumulation of mutations.
Mutations that confer a growth advantage on the cell co-operate in
tumour formation, and the process therefore recapitulates the multi-
step progression of human tumours (for reviews, see [164,166]).
The MuLV provirus consists of viral genes ﬂanked by two long
terminal repeats (LTRs), which are composed of three parts: U3, R and
U5 [164]. Elements within the LTRs drive expression of the viral genes
but can also disrupt host genes. U3 contains enhancer and promoter
sequences, while R contains transcription start and termination sites.
High levels of viral transcription and, therefore, host gene disruption,
will only occur in cells containing transcription factors that bind to U3.
The propensity of MuLV to induce T- and B-cell lymphomas can be
attributed to its dependence upon T- and B-cell-speciﬁc transcription
factors, including Runx, Ets and Myb (see [167], Fig. 2). MMTV, and
indeed other retroviruses, have a similar structure to MuLV.
Retroviruses can mutate host genes in a number of different ways
(Fig. 3). The most common mechanism is enhancer mutation, where
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may be some distance away from the retroviral insertion. Most
proviruses causing enhancer mutations are found upstream of the
mutated gene in the antisense orientation or downstream in the sense
orientation. Several possible explanations for this are that upregula-
tion of the host gene may be impeded if the viral promoter intercepts
the viral enhancer and host gene, and that viral enhancersmay only be
functional if they are not transcribed (see [164,168]).Myc and Gﬁ1 are
frequent targets of enhancer mutation in retroviral insertional
mutagenesis [169–171]. Myc is mutated in many types of human
cancer and encodes a transcription factor thought to regulate the
expression of 15% of all genes, including those involved in cell division,
cell growth and apoptosis (see [172]). Gﬁ1 is a zinc ﬁnger transcrip-
tional repressor that is involved in cell fate determination and
differentiation, including in T- and B-cells [173,174].
An alternative mechanism of mutagenesis is the promoter
mutation, where the retrovirus inserts in the sense orientation into
the promoter region of a host gene. This uncouples the host gene from
its own promoter and places it under the control of the viral
promoters, resulting in the production of elevated levels of the
wildtype protein from chimeric transcripts comprising part of the
viral sequence and the complete coding region of the host gene [175].
Promoter mutations led to identiﬁcation of Evi1 as a potential
oncogene [176–178]. EVI1 encodes a zinc ﬁnger transcription factor
that is frequently overexpressed in myeloid malignancies. It is
involved in several recurrent rearrangements, including 2 transloca-
tions that result in the fusion transcripts AML1/MDS1/EVI1 and ETV6/
MDS1/EVI1, whereMDS1 and EVI1 are also expressed as a readthrough
transcript in normal tissues (for a review, see [179]).
Since the retrovirus contains a polyadenylation signal within the R
region of the LTR and a cryptic polyadenylation signal in the antisense
orientation intragenic retroviral insertions in both orientations can
cause premature termination of gene transcription. Insertions within
the 3′ UTR that truncate a transcript such that mRNA-destabilising
motifs are removed will give rise to a more stable transcript and,
as a result, increased levels of the wildtype protein (see [164]). The
oncogenes Pim1 and Mycn are frequently mutated in this way
[180–182]. Pim1 encodes a serine/threonine kinase that is frequently
overexpressed in human prostate cancer [183], whileMycn encodes a
transcription factor related to Myc that is ampliﬁed in a variety of
human tumours, most notably neuroblastomas [184,185].
Intragenic insertions can also activate a gene by causing C-
terminal or N-terminal truncation of the encoded protein. Insertions
in oncogenes Myb and Notch1 cause both N-terminal and C-terminal
truncations [164,186]. C-terminally truncated Notch1 lacks the
destabilising PEST domain and is therefore produced at increased
levels, while N-terminal truncations remove the extracellular
domain, resulting in a constitutively active intracellular domain
expressed from the viral promoter or from a cryptic promoter in
Notch1 [187]. Activating mutations within the extracellular and
PEST domains of NOTCH1 have been observed in human T-cell
acute lymphoblastic leukaemia [188], in which NOTCH1 plays an
important role. Thus analysis of the distribution of insertions within
an oncogene may therefore help to explain how the gene is mutated
in human cancer.
Intragenic insertions may also cause gene inactivation, either
through premature termination of transcription or by disrupting gene
splicing (see [164]). It is therefore possible to identify tumour
suppressor genes by retroviral insertional mutagenesis, although
they are found much less frequently than oncogenes because both
copies of the gene must be inactivated. Mutation at the Nf1 locus is
observed in acute myeloid leukaemia in BXH2 mice [189], which
contain MuLV insertions [190], while in an insertional mutagenesis
screen of Blm-deﬁcient mice, 11 genes met the criteria for tumour
suppressor genes, including Rbl1 and Rbl2, which are paralogues of
Rb1 [191]. Blm-deﬁcient mice have a mutation in the RecQ protein-like-3 helicase gene [192] and show a predisposition to cancer due to
increased frequencies of mitotic recombination [193]. There is an
increased likelihood of ﬁnding tumour suppressor genes in these mice
because they have a higher probability of a normal allele being lost so
that only one insertion is required to inactivate the gene [193].
However, candidate tumour suppressor genes still only accounted for
5% of all genes identiﬁed in the screen by Suzuki et al. [191]. In theory,
insertional mutagenesis screens should have a better chance of ﬁnding
haploinsufﬁcient tumour suppressor genes, but none have yet been
unambiguously identiﬁed [164].
Insertional bias could also account for the paucity of tumour
suppressor genes identiﬁed in retroviral screens. For example, MuLV
shows a strong preference for integration near to the transcription
start sites of actively transcribed genes [194] and is therefore less
likely to disrupt a gene by intragenic insertion. However, it is possible
that promoter mutations could also cause gene inactivation, as CpG
islands in the retroviral LTRs are methylation targets, and DNA
methylation could “spread” to CpG islands in the host gene, resulting
in gene silencing (see [195]). Retroviruses prefer to insert into open
chromatin [196,197], but different retroviruses show different target
site preferences, suggesting that virus-speciﬁc interactions are
involved [198]. DNA sequence does not seem to inﬂuence target site
selection [199]. The tendency for MuLV to insert in the promoter
region suggests that it interacts with cellular proteins bound near start
sites [194,198].
2.4.1.2. Identifying candidate cancer genes. The retroviral insertions
act as ‘tags’ for identifying the mouse genes that are mutated by
insertional mutagenesis, and sequencing of the mouse genome and
the development of high-throughput genomic techniques have made
it possible to identify thousands of insertions in a single screen.
Insertion sites were initially identiﬁed using methods that involve
Southern blot analysis and genomic library screening, followed by
genome walking to ﬁnd the mutated gene (see [164,167]). However,
these have been replaced by PCR-based methods, in which mouse
genomic DNA ﬂanking the insertion sites is ampliﬁed and is then
mapped back to the genome. One such method, known as viral
insertion site ampliﬁcation (VISA) involves using a PCR primer
designed to bind to the MuLV LTR and a degenerate, restriction-site
speciﬁc primer that enables ampliﬁcation of the DNA between the
insertion and a nearby restriction site [200,201]. In inverse PCR and
linker-mediated PCR-based methods (Fig. 4) the genomic DNA is
digested with a restriction enzyme prior to PCR ampliﬁcation. In
inverse PCR, the digested genomic DNA is allowed to ligate to itself to
form a circular template. PCR primers bind to the retroviral DNA and
point out towards the genomic sequence, resulting in ampliﬁcation of
genomic DNA directly ﬂanking the retrovirus [202,203]. Only DNA
fragments of a suitable length for efﬁcient circularisation and for PCR
ampliﬁcation will be detected [164].
In linker-mediated PCR, rather than the digested DNA ligating to
itself, it is ligated to a linker, and this enables shorter insertions to be
identiﬁed. One primer is designed to bind to the linker, and the other
binds to the retroviral sequence. A number of methods have been
developed, eachwith a different approach for avoiding ampliﬁcation of
DNA that has linkers at both ends but no retroviral DNA. Vectorette PCR
involves the use of a double-stranded linker with a cohesive end for
ligation to restricted DNA and a central region with a mismatch [204].
The primer is the same sequence as the mismatched part of the upper
strand, and this prevents initiation of priming from the vectorette until
the complementary strand has been synthesised by priming from
within the retroviral insertion.However, thismethod suffers fromnon-
speciﬁc annealing of the primers and ‘end-repair’ priming, in which
the ends of unligated vectorettes initiate priming and enable PCR
ampliﬁcation without involving the retroviral-speciﬁc primer (see
[205]). Any errors that cause ampliﬁcation of DNA that is not ﬂanking
an insertion will lead to the false identiﬁcation of insertion sites.
Fig. 4. Isolation of retroviral insertion sites. (A) Inverse PCR. Tumour DNA is digested
using restriction enzyme X and the restricted DNA is allowed to circularise. Genomic
DNA ﬂanking retroviral insertions are ampliﬁed using PCR primers that bind within the
insertion and point out towards the genomic DNA. A second round of PCR is performed
using nested primers. The ampliﬁed DNA is sequenced and mapped to the mouse
reference genome. (B) Splinkerette PCR. As for inverse PCR, except that instead of
circularising the digested DNA, a splinkerette adapter (shown in yellow) is ligated and
genomic DNA ﬂanking the retroviral insertions is ampliﬁed using PCR primers that bind
to the adapter and the retroviral LTR.
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hairpin structure on the bottom strand, rather than a mismatch
sequence [205]. The primer has the same sequence as the upper
strand and, as with vectorette PCR, cannot anneal until the
complementary strand has been synthesised. The stable hairpin
does not enable end-repair priming and only the upper strand can act
as a non-speciﬁc primer. In all the PCR-based methods, insertions are
only identiﬁed if target sites for the chosen restriction endonuclease
are close enough to the insertion for the intervening region to be
ampliﬁed. Coverage can be improved by using multiple restriction
endonucleases [164].
Once the insertion-ﬂanking genomic DNA has been ampliﬁed, the
PCR products must be separated for sequencing. In the past, products
were separated using agarose or polyacrylamide gels, but rare
insertions are likely to be missed, and gel extraction is painstaking
and subjective. An alternative method is to subclone the PCR products
directly into a vector. By shotgun cloning the total mixture, it is
possible to maintain the relative proportions of insertions from the
startingmaterial. However, it alsomeans thatmore sequencingwill be
required to capture the rare insertions (see [164]). The VISA approach
sequences PCR products directly, without subcloning, which reduces
the risk of sequencing contaminating products [201]. The latest
method uses massively parallel sequencing technology from 454 Life
Sciences (http://www.454.com) [206,207], in which fragmented
genomic DNA is ligated to short adaptors that are used for puriﬁcation,ampliﬁcation and sequencing. The DNA is denatured and immobilised
onto beads, where PCR ampliﬁcation and sequencing occur. This
approach is extremely high-throughput, does not rely on cloning and
is capable of detecting rare insertions. However, it can encounter
problems when dealing with repetitive regions and long runs of a
single nucleotide.
The next step is to map the sequenced DNA to the genome using a
DNA alignment algorithm. For large screens, it is an advantage to be
able to ﬁnd high quality alignments quickly [164]. The Sequence
Search and Alignment by Hashing Algorithm (SSAHA) (SSAHA2,
[208]) converts the genome into a hash table, which can then be
rapidly searched for matches. Sequences in the database (the mouse
genome) are preprocessed into consecutive k-tuples of k contiguous
bases and the hash table stores the position of each occurrence of each
k-tuple. The query sequence (sequenced DNA) is also split into k-
tuples and the locations of all occurrences of these sequences in the
database, i.e. the “hits”, are extracted from the hash table. The list of
hits is sorted, and the algorithm searches for runs of hits in the
database that match those in the query sequence. Having identiﬁed
regions of high similarity, sequences are fully aligned using cross_-
match [209], which is based on the Smith–Waterman–Gotoh align-
ment algorithm [210,211]. Because the database is hashed, search time
in SSAHA2 is independent of database size, provided k is not too small.
SSAHA2 is therefore three to four orders of magnitude faster than the
BLAST alignment algorithm [212], which scans the database and
therefore performs at a speed that is directly related to database size
[208].
If the PCR mixture has been shotgun cloned and preferably
sequenced to a high depth, there may be more than 1 read per
insertion site. Reads from a single tumour that map to the same
genomic region must therefore be clustered into single insertion sites.
Like the mutations in human cancer, tumour DNA will contain both
insertions that drive oncogenesis (oncogenic insertions) and inser-
tions that are passengers (background insertions). In theory, most
identiﬁed insertions should be oncogenic because these, and
particularly the earliest events in tumourigenesis, should be present
in most, if not all, tumour cells, whereas background insertions should
be present in a smaller proportion of cells. However, background
insertions that occur early in tumour development in a cell containing
oncogenic insertions could also be highly represented in the ﬁnal
tumour (see [213]).
Clustering of insertions from different tumours into common
insertion sites (CISs) helps to distinguish oncogenic and background
insertions. In theory, background insertions should be randomly
distributed across the genome. Therefore, for small-scale screens, a
gene in the vicinity of a cluster of insertion sites in different tumours is
a strong candidate for a role in cancer. Methods for identifying
statistically signiﬁcant CISs, i.e. regions that are mutated by insertions
in signiﬁcantly more tumours than expected by chance, have involved
generating a random distribution of insertions across the genome and
obtaining an estimate of the number of false CISs in windows of ﬁxed
size using Monte Carlo simulation [214] or the Poisson distribution
[175]. These methods can be used to deﬁne the maximum window
size in which insertions must fall to be considered non-randomly
distributed. However, for larger scale screens, the window must be
decreased to a size that is smaller than the spread of insertions within
a single CIS so that many CIS are missed [213]. In addition, the above
methods assume that insertions are randomly distributed and take no
account of insertional biases [215].
A more recent approach for CIS detection overcomes these
problems by using a kernel convolution (KC) framework, which
calculates a smoothed density distribution of inserts across the
genome [213]. The scale (kernel size) can be varied so that CISs of
varying widths can be identiﬁed. Decreasing the kernel size may
identify separate CISs affecting the same gene, while increasing the
kernel sizewill identify CISs where insertions arewidely distributed in
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because it keeps control of the probability of detecting false CISs. The
threshold for signiﬁcant CISs is based on the alpha-level deﬁned by
the user and on a null-distribution of insertion densities obtained by
performing random permutations. A background distribution, such as
the location of transcription start sites, can be provided to correct for
insertional biases [213].
The ﬁnal step is to identify the genes that are being mutated by
insertions within CISs. This may be relatively straightforward for
intragenic insertions, but for enhancer mutations, which may have
long distance effects, it is often difﬁcult to identify the mutated gene
unequivocally. Measuring the expression and transcript size of
candidate genes in insertion-containing tumours can shed some
light, but animal models and analysis of the orthologues in human
cancer data are required for more conclusive evidence [164].
A number of screens have been performed in recent years that have
each identiﬁed hundreds of insertion sites [175,191,201,214,216–223].
The results of many screens have been collated and stored in the
Retroviral Tagged Cancer Gene Database (RTCGD; http://rtcgd.abcc.
ncifcrf.gov/) [171]. At the time of writing, the database contains CISs
associated with 540 genes from 30 screens (database accessed
December 2008). Users can search for individual genes of interest,
or for CISs identiﬁed using particular mouse models and/or in
particular tumour types. Genes with the most CISs are Gﬁ1 and Myc,
with 82 and 78 insertions across all screens, respectively.
2.4.1.3. Identifying co-operating cancer genes. Retroviral insertional
mutagenesis is a powerful tool for identifying genes that collaborate in
tumour development. Collaborations can be identiﬁed by analysing
the co-occurrence of CISs in individual tumours. For example, proviral
activation of Meis1 and Hoxa7 or Hoxa9 is strongly correlated in
myeloid leukaemias from BXH2 mice [190,224]. Meis1 and Hoxa9 are
targets of translocation in human pre-B leukaemia [225] and acute
myeloid leukaemia (AML) [226], respectively, and they are frequently
co-expressed in human AML [227]. Both genes encode homeodomain
transcription factors that bind to Pbx, and Meis1–Pbx and Hox–Pbx
complexes have been shown to co-occupy the promoters of
leukaemia-associated genes, such as Flt3 [228].
A two-dimensional Gaussian Kernel Convolution method has
recently been developed for identifying co-operating mutations in
insertional mutagenesis data [229]. It is based on the Kernel
Convolution framework used for identifying CISs [213]. The method
has been applied to the data in RTCGD and, as well as ﬁnding
previously characterised interactions, such asMeis1 andHoxa9/Hoxa7,
it also ﬁnds novel interactions, such as Rasgrp1 and Cebpb, which are
both known to play a role in Ras-induced oncogenesis [229]. However,
as retroviral-induced tumours are oligoclonal, it is difﬁcult to prove
that tagged genes are in the same cell, and therefore that they
collaborate [230]. In an alternative approach, retroviral screens are
performed on transgenic mice overexpressing known oncogenes, and
knockout mice harbouring inactivated tumour suppressor genes, to
identify genes that collaborate with the overexpression of oncogenes,
and loss of tumour suppressor genes, respectively. For example, 35% of
B-cell lymphomas generated inMuLV-infected EμMyc transgenicmice,
in whichMyc is overexpressed in B-cell progenitors under the control
of the immunoglobulin heavy chain enhancer, have an insertion in
Pim1 or the polycomb group protein Bmi1 [231]. Bmi1 collaborates
with Myc by inhibiting Ink4a/Arf, and therefore inhibiting Myc-
induced apoptosis [232]. In concurrence with these ﬁndings, Myc
insertions were identiﬁed in 20% of tumours from MuLV-infected
Cdkn2a (Ink4a/Arf)-deﬁcient mice, but none contained insertions in
Bmi1 [218]. Insertional mutagenesis also identiﬁes genes that can
functionally complement one another in tumour development. For
example, in MuLV-infected EμMyc mice, activation of Pim2 increases
from 15% to 80% in compound mutant mice lacking Pim1 expression
[233], while Pim3 is selectively activated in mice lacking Pim1 andPim2 expression [175]. Pim1 is a coactivator of Myc that is required
for expression of around 20% of all Myc target genes [234]. Pim kinases
also appear to suppress Myc-induced apoptosis, but it is not clear
whether this mechanism or Myc coactivation is responsible for the co-
occurrence of Pim1 andMycmutations observed in lymphomagenesis
(for a review, see [235]). Pim1 also collaborates with Myc in human
prostate cancers [236].
Retroviral screening of a mouse model for human myeloid
leukaemia has identiﬁed 6 CIS genes, including Plag1 and Plagl2,
which co-operate with the oncogenic fusion gene CBFB-MYH11 [237].
This screen used a replication-defective retrovirus, cloned ampho-
tropic virus 4070A, to limit the number of mutations and therefore to
show that mutation of only one or a few genes were sufﬁcient to
induce tumorigenesis. Other studies using replication-competent
viruses report 3–6 insertions in a single tumour [175,214] but, as
mentioned above, retroviral-induced tumours are oligoclonal and it is
therefore difﬁcult to make a reliable estimate of the number of
insertions in a tumour clone (see [167]).
2.4.1.4. Generating tumours of different types. Asdiscussedpreviously
the dependence of retroviruses on cell-type-speciﬁc transcription
factors limits the range of tumours that they can induce. There have
been some successful attempts to alter the propensity ofMuLV for T-cell
lymphomas by using an EμMyc transgenic mouse, which results in
predominantly B-cell lymphomas [231], and by expressing platelet
derived growth factor B-chain (PDGFβ) from an MuLV-based retrovirus
to generate mice with glioblastomas, which require activation of PDGF
receptors for tumourigenesis [219]. Mutations in the retroviral LTRmay
also lead to a change in tumour type, but manipulated viruses have a
tendency to revert to wildtype [164]. In addition, MuLV and other
retroviruses cannot infect nondividing cells, and infection is inefﬁcient
in slowly replicating cells and in tissues thathave abasementmembrane
or mucin layer [238,239]. Transposon insertional mutagenesis is an
alternative method that provides the possibility of generating a wider
spectrum of tumours.
2.4.2. Transposon-mediated insertional mutagenesis
Like retroviruses, transposons are genetic elements that can
mobilise within the genome. They are classiﬁed according to their
mechanism of transposition. DNA transposons move by a “cut and
paste” mechanism, in which they are excised from one site in the
genome and integrated into another. Retrotransposons transpose via
an RNA intermediate and are classiﬁed into LTR retrotransposons,
which encode reverse transcriptase and transpose in a similar manner
to retroviruses, and non-LTR retrotransposons, which are transcribed
by host RNA polymerases and may or may not encode reverse
transcriptase [240].
2.4.2.1. The Sleeping Beauty transposon system. While DNA transpo-
sons are activelymobile in plants and invertebrates, all of the elements
that have been so far identiﬁed in vertebrates are non-functional [164].
However, they can be mobilised in the mouse by using an invertebrate
DNA transposon or by reconstructing a degenerate vertebrate
transposon. Sleeping Beauty (SB) is a synthetic transposon derived
from dormant DNA transposons of the Tc1/Mariner family in the
genomes of salmonid ﬁsh. An active transposon, named SB10, was
synthesised by directed mutagenesis on the basis of a consensus
sequence obtained by aligning 12 degenerate transposon sequences
from 8 species [241]. SB consists of two inverted repeat/direct repeat
(IR/DR) elements of ∼230 bp each, ﬂanking a cargo sequence [242].
Transposition occurs via binding of a transposase enzyme to two sites
in each IR/DR [243]. All four binding sites are required for transposition
and, in general, the closer the IR/DRs, the higher the transposition
efﬁciency [243]. Higher levels of transposition have been achieved by
introducing point mutations into the transposase, producing, for
example, the SB11 [244] and SB12 [245] transposases.
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demonstrated in two studies published in 2005 [246,247]. In both
studies, transposons were introduced into mice by pronuclear
injection of a linear plasmid containing one copy of the transposon,
which forms a multicopy concatemer of variable length at a single site
in the mouse genome. SB was mobilised by crossing these mice to
mice expressing a transposase from a ubiquitous promoter. Collier et
al. [246] used a transgene containing the SB10 transposase under the
control of the CAGGS promoter to mobilise around 25 T2/Onc
transposons, while Dupuy et al. [247] used the more active SB11
version knocked into the endogenous Rosa26 locus to mobilise 150–
350 copies of the T2/Onc2 transposon. T2/Onc and T2/Onc2 were
engineered to contain elements for mutagenesis much like those in
retroviruses (Fig. 2). The cargo of both transposons contains the 5′ LTR
of the murine stem cell virus (MSCV) followed by a splice donor, as
well as splice acceptors followed by polyadenylation sites in both
orientations. The transposons are therefore capable of disrupting
genes by promoter mutation, N-terminal and C-terminal truncation
and gene inactivation but, unlike retroviruses, they show low
enhancer activity [247]. T2/Onc and T2/Onc2 are essentially the
same, except that T2/Onc2 contains a larger fragment of the Engrailed
splice acceptor and the IR/DRs have been optimised for transposase
binding [247]. In the study by Dupuy et al. [247], there was a high rate
of embryonic lethality and of the 24 T2/Onc2;Rosa26SB11 mice that
survived to weaning, all developed cancer, most commonly T-cell
lymphomas but also other haematopoietic malignancies and, in a few
cases, medulloblastomas and intestinal and pituitary neoplasias. Some
mice had 2 or 3 types of cancer and all died within 17 weeks. In
contrast, in the study by Collier et al. [246], mice on a wildtype
background did not develop tumours, but those on an Arf-null
background developed sarcomas at an accelerated rate. The difference
between the two studies most likely reﬂects the differences in
transposon copy number and in transposase expression and activity
[248]. Transposase expression in CAGGS-SB10 mice has since been
shown to be low and variegated in most tissues, probably due to
epigenetic silencing of the transgene, while transposase expression is
high in nearly all cell types in Rosa26SB11 mice [248]. However,
transposase is expressed in the testes of CAGGS-SB10 mice, which
show high rates of transposition in the male germline [248,249].
Transposons, like retroviruses, can be used to identify co-operating
cancer genes. For example, Braf was frequently mutated in Arf-null
mice, suggesting that these genes co-operate in tumour formation
[246], while of the six T-cell tumours containing Notch1 mutations,
three also contained insertions mutating Rasgrp1, and 2 of these
contains Sox8 mutations, suggesting that these three genes also co-
operate [247].
While a number of the genes identiﬁed in the haematopoietic
malignancies of T2/Onc2;Rosa26SB11 mice had been previously
identiﬁed in retroviral mutagenesis, other genes had not [247]. This
indicates that transposon mutagenesis is a complementary approach
for cancer gene discovery, and may reﬂect differences in insertional
bias. While MuLV shows a strong preference for inserting near
transcription start sites [194], SB shows a less pronounced preference
and shows no preference for actively transcribed genes [250]. SB
inserts at TA dinucleotides and therefore shows a bias towards AT-rich
sites, particularly those with the consensus sequence ANNTANNT
[251,252]. However, most signiﬁcant is the strong tendency of SB to
transpose to sites close to the concatemer. This phenomenon, known
as “local hopping”, results in a non-random distribution of insertions
that hampers CIS detection. Another potential hindrance to cancer
gene identiﬁcation is the ability of transposons to excise themselves
and reinsert multiple times. SB leaves a small footprint upon excision,
and it is possible that, at least in exons, this could continue to cause
gene disruption that would not be identiﬁable [248]. Likewise, the
excision in some cells of transposons that had been critical for tumour
development could result in a more heterogeneous tumour in whichcancer gene identiﬁcation would be more complicated. However, it is
possible that such an event would be deleterious and that the cell
would be eliminated [248] and, as SB transposition efﬁciency is higher
for methylated [253] and heterochromatic [254] transposons, excision
of transposons involved in gene disruption may be relatively rare. A
further drawback of SB, and possibly other DNA transposons, is that
transposition may induce genomic rearrangements, including dele-
tions and inversions near to the transposon concatemer, and
tumourigenesis could therefore be initiated by genes disrupted by
these rearrangements rather than by mobilised transposons [255].
One of the key beneﬁts of using a transposon such as SB for
insertional mutagenesis is that the mutagenic elements can be
modiﬁed to control the types of mutation that occur. For example,
modifying the cargo to enable only truncating mutations could
increase the likelihood of identifying tumour suppressor genes
[248]. Tissue-speciﬁc promoters can be integrated as cargo, making
transposons an attractive mutagen for cancer gene discovery in a
range of cancer types [256]. Spatial and temporal transposition could
also be achieved by introducing a lox–stop–lox cassette between the
SB transposase promoter and cDNA, such that transposition is induced
upon the addition of Cre [256].
Identiﬁcation of cancer genes in SB mutagenesis follows much the
same procedure as for retroviruses. Largaespada and Collier [257]
have developed a technique that uses linker-mediated PCR but that
enables PCR ampliﬁcation of DNA ﬂanking both sides of the
transposon to maximise coverage. Primers were designed to bind to
the IR/DR sites and to synthetic adapters. Unlike in retroviral
mutagenesis, tumour cells contain a concatemer of non-transposed
elements. To avoid repeated cloning of the junctions between these
elements, “blocking” primers can be used that bind to the plasmid
DNA ﬂanking each transposon in the concatemer but that have
blocked 3′ ends to prevent polymerase extension. Alternatively, after
linker ligation, the DNA could be redigestedwith an endonuclease that
cuts within the ﬂanking plasmid DNA so that the primer binding sites
are separated on different molecules (see [257]).
2.4.2.2. Alternative mutagens for transposon insertional mutagenesis.
The active invertebrate transposons piggyBac and Minos are the only
other DNA transposons that have so far been mobilised in the mouse
[248]. The piggyBac transposon, isolated from the cabbage looper
moth (Trichoplusia), mobilises in mouse somatic cells and in the
germline, and it can carry a larger cargo than SB [258]. The coding
sequence of piggyBac has been codon-optimised to enable higher
levels of transposition in the mouse, and inducible versions have
been generated by fusing the transposon to the ERt2 oestrogen
receptor ligand-binding domain [259]. Unlike SB, it shows a strong
preference for inserting into genes in the mouse [258] and in human
cell lines [260]. The Minos transposon, from Drosophila hydei, has
attracted interest because it shows a low insertional bias and high
transposition efﬁciency in a range of animals (for a review, see [261]).
However, it has so far shown only weak in vivo activity in the mouse
[262,263].
Retrotransposons are also gaining attention as potential insertional
mutagens. Long interspersed nuclear elements (LINEs) are non-LTR
retrotransposons that are transcribed into mRNA by RNA polymerase
II and encode two proteins that are essential for transposition [264]: a
protein that binds to single-stranded RNA [265] and a protein with
reverse transcriptase and endonuclease activity [266,267]. 17% of the
human genome is composed of LINE-1 (L1) elements [268].
Transcription of endogenous L1 elements is generally inefﬁcient but
there are a small number of highly active “hot L1s”, which were used
to generate a transgenic mouse model of L1 retrotransposition that
showed a higher frequency of de novo somatic L1 insertions [269]. A
200-fold increase in transposition in the mouse germline has also
been achieved by codon optimisation of the human L1 coding region
[270]. L1 mobilises by a “copy and paste”mechanism. It is therefore an
153J. Mattison et al. / Biochimica et Biophysica Acta 1796 (2009) 140–161attractive mutagen for forward genetic screens because, unlike DNA
transposons, it is capable of self-expansion and the original insertion
remains intact, aiding identiﬁcation of mutated genes [248,271]. In
addition, it appears to show no [272], or only a slight insertion site
preference [269], for inserting into genes and there is no local hopping
because the RNA intermediate must exit and re-enter the nucleus
before inserting into the genome. However, most L1 insertions are
truncated at the 5′ end [269], potentially resulting in the loss of
promoters, splice acceptors and polyadenylation signals required for
mutagenesis [248]. Controlled insertional mutagenesis using L1
derivatives has not yet been reported and Sleeping Beauty remains
the preferred transposon for cancer gene discovery.
3. Cross-species comparative analysis for cancer gene discovery
Important biological sequences, such as gene coding regions and
regulatory elements, are conserved in evolution. Cross-species
comparative sequence analysis can therefore facilitate the character-
isation of known cancer genes. For example, comparison of intronic
sequences in human and mouse BRCA1 led to the identiﬁcation of
two evolutionarily conserved regulatory elements in the second
intron that, when mutated, had opposite effects on gene expression
[273]. Cross-species comparative analysis also provides an extremely
powerful approach for identifying novel genes and gene collabora-
tions involved in cancer formation. Many genes and pathways have
been implicated in tumourigenesis, and most human cancers exhibit
genomic instability, leading to the acquisition of genetic alterations
that drive tumourigenesis but also many passenger mutations that
do not contribute to the tumour phenotype. Distinguishing driver
and passenger mutations is a major challenge. The underlying
molecular mechanisms that govern important biological processes
are, however, conserved through evolution and cancer-associated
mutation data from other species can therefore be used as a ﬁlter for
identifying genes that represent strong candidates for a role in
human tumourigenesis.
Genome-wide expression data for human tumours can be difﬁcult
to interpret, and a number of studies have therefore used cross-
species comparative analysis to identify conserved expression
signatures that are important in tumourigenesis. Expression proﬁles
of intestinal polyps from patients with a germline mutation in APC
were compared to those from Apc-deﬁcient mice and the conserved
signature showed an over-representation of genes involved in cell
proliferation and activation of the Wnt/β-catenin signalling pathway
[274]. Likewise, comparison of expression proﬁles for human lung
adenocarcinoma and a mouse model of Kras2-mediated lung cancer
led to the identiﬁcation of a KRAS2 expression signature that was not
identiﬁed by analysing KRAS2-mutated human tumours alone [26].
More recently, a mutated Kras-speciﬁc signature that can be used to
classify human and mouse lung tumours on the basis of their KRAS
mutation status has been identiﬁed by comparing KRAS-mutated
human cancer cells to mouse somatic cells containing knocked-in
mutant Kras [275].
Mouse prostate cancers induced by human MYC have an expres-
sion signature that deﬁnes a set of “Myc-like” human prostate
tumours and includes overexpression of the oncogene Pim1 [236].
Rat prostate tumours also have a similar expression proﬁle to human
prostate tumours, and have been used to identify conserved genes
that are differentially expressed in both species in response to
treatment with the chemopreventive agent Selenium [276]. The
mouse is therefore not the only cancer model that has been used for
cross-species comparison. The greater the evolutionary distance
between the species, the greater the likelihood that conserved
changes in gene expression contribute to the cancer phenotype. An
expression signature in zebraﬁsh liver tumours is more consistently
associated with human liver tumours than with other human tumour
types and, since human and zebraﬁsh are distantly related, genes inthe conserved signature are strong candidates for a role in cancer
development [277].
Another approach for cross-species analysis involves comparing
the CGH proﬁles of human tumours to the CGH proﬁles of tumours
generated from a mouse model of the corresponding human cancer.
Such studies take advantage of the conserved synteny between the
human and mouse genomes [278]. Comparison of CGH proﬁles for
human neuroblastomas with proﬁles for tumours and cell lines from a
MYCN transgenic mouse model of neuroblastoma have shown that
many genetic aberrations are conserved between species [279,280].
Likewise, 80% of aberrations detected by array CGH in tumour cells of
themousemodel for epithelial ovarian cancer are conserved in human
epithelial ovarian cancer [281] and epithelial carcinomas in mice with
telomere dysfunction show numerous copy number changes in
regions syntenic to those in human cancers [282]. Zender et al.
[283] used array CGH to identify regions of copy number change in the
tumours of a mouse model for hepatocellular carcinoma. The CGH
proﬁles were compared to array CGH data for human hepatocellular
carcinomas to identifyminimally conserved amplicons, and genes that
showed increased expression in both species were chosen as
candidate cancer genes. The authors identiﬁed 2 oncogenes, cIAP1
and Yap, that act synergistically in a focal amplicon on mouse
chromosome 9qA1, which is syntenic to an 11q22 amplicon in human
tumours. Kim et al. [284] used a comparable approach to identify
Nedd9 as a candidate for a role in promotingmetastasis of melanomas.
A focal amplicon comprising 8 genes, including Nedd9, was identiﬁed
on chromosome 13 in 2 metastatic cell lines derived from a Rasmouse
model of nonmetastic melanoma. 36% of metastatic melanomas
contained a much larger amplicon in a syntenic region on human
chromosome 6p25-24, and 35–52% of metastatic melanomas showed
signiﬁcant overexpression of NEDD9, with more advanced tumours
showing higher levels.
Comparison of human cancers with mouse models of cancer relies
on the use of mouse models that accurately recapitulate the human
cancer [285]. While cIAP1 and Yap overexpression was found to be
important in p53−/−;Myc-induced hepatoblasts in the study by
Zender et al. [283], neither gene contributed to tumourigenesis in
p53−/−;Akt or Ras hepatoblasts. Likewise, Nedd9 did not contribute to
melanoma metastasis in the absence of Ras or Raf activation [284].
Cross-species comparison of genomic proﬁles for a particular cancer
may therefore require some prior knowledge of the genetic events
that drive tumourigenesis in that cancer so that an appropriate mouse
model can be generated. However, cross-species analysis can also
facilitate the selection of a suitable mouse model. Lee et al. [286] used
unsupervised hierarchical clustering of expression data from human
and mouse hepatocellular carcinomas to identify the mouse models
that provided the best ﬁt for human cancers. Mouse and human
tumours that clustered together due to similar expression proﬁles also
shared phenotypic characteristics, such as proliferation rate and
prognosis [286]. Most genetically engineered mouse models do not
show the high levels of chromosome instability associated with
human cancers. Mice that are engineered with telomere dysfunction,
or defects in DNA damage checkpoints or DNA repair, may therefore
represent better models for comparative oncogenomics [287].
Comparative analysis of copy number alterations in chromosomally
unstable murine T-cell lymphomas and human solid tumours
identiﬁed recurrent aberrations in the mouse that are conserved in
human T-ALL but also in other human tumour types [287].
Candidate cancer genes can also be identiﬁed by comparing
expression and CGH proﬁles for human tumours with mouse
insertional mutagenesis screens. Genes in expression signatures
associated with distinct subclasses of human acutemyeloid leukaemia
were signiﬁcantly correlated with genes nearest to insertion sites in a
Grafﬁ 1.4 MuLV mouse model and with candidate leukaemia genes in
BXH2 and AKXD mouse models [288]. There was little overlap
between the candidates identiﬁed by Grafﬁ 1.4 and BXH2/AKXD,
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viruses may be required for a more effective cross-species comparison
[195]. Ampliﬁed regions in human pancreatic cancer have also been
shown to contain more CIS in retrovirus-induced murine lymphomas
and leukaemias than expected by chance [289]. As discussed
previously, insertional mutagenesis ‘tags’ the mutated gene, therefore
facilitating cancer gene identiﬁcation. In contrast, copy number
alterations in human cancer can be very large, encompassing many
genes, and no systematic approach currently exists for identifying the
critical genes within these regions [290]. Thus comparative analysis of
oncogenic insertions in mouse tumours and CGH data for human
tumours is potentially a very powerful approach for narrowing down
the candidates in regions of copy number change.
4. Validating candidate cancer genes
In many cases, identifying candidate cancer genes using the
methods described above is the ﬁrst step towards proving that they
are involved in cancer development and further functional validation
is usually required.
4.1. Validating candidate gain of function mutations
Validating candidate gain of function mutations may be achieved
in several ways and the approach applied is largely driven by the
tissue or organ system in which the candidate oncogene is being
studied. Classically, viruses have been used to overexpress candidate
cancer genes either by infecting cells ex vivo and then transplanting
them back into a host, or by injecting viruses directly into the tissue of
interest [291]. The haematopoietic system and the mammary gland
are particularly amenable to transplantation, while any organ may be
injected with viruses. There are now vast collections of cDNAs in
retroviral vectors that provide an ‘off the shelf’ resource for over-
expressing and validating candidate cancer genes [292, 293].
Transposons such as Sleeping Beauty have also been used to deliver a
‘payload’ containing an oncogene into tissues including the liver [294]
and brain [295]. In this context, transposons essentially represent an
alternative delivery tool to viruses. Where it is desirable to generate
large numbers of animals for study, an alternative strategy has been
proposed to generate arrays of transposons carrying oncogenic cDNAs
in ES cells and to make lines of mice from which transposons may be
mobilized somatically, resulting in expression of oncogenic cDNAs
when the transposon lands near a suitable promoter [296]. The
premise is that an oncogene requires the right level of expression to
participate in transformation. While novel, it is unclear how useful
this approach will be since construction of transposon arrays is
cumbersome, and it is clear that oncogenic cDNAs present in these
arrays are not silent or inert so developmental defects resulting from
ectopic expression of candidate oncogenes may occur. An alternative
strategy to these overexpression approaches is to knockdown
expression of a candidate oncogene, since depletion of a gene that is
important in driving oncogenesis may result in decreased growth of
the tumour, or of a cell line derived from the tumour in culture. A very
powerful, but low-throughput, approach is to knock cDNAs into a
deﬁned locus such as the Rosa locus in a Lox–Stop–Lox vector and to
express them conditionally after expression of Cre recombinase
[297,298]. Elegant methods have also been developed to validate
fusion genes using ‘invertor alleles’ [299,300].
4.2. Validating candidate loss of function mutations
The most high-throughput approach for validating candidate
tumour suppressor genes is to knock them down using shRNAs
[301,302]. This approach is largely restricted to tissues in which viral
delivery of the shRNA can be achieved, as discussed above. There are,
however, constructs available to introduce shRNAs into deﬁnedlocations in the genome such as the Rosa locus. The success of an
shRNA depends on the ability of the transcript to be ‘knocked down’
and on the stability of the protein, so it may not be suitable for all
genes. One particularly appealing shRNA-based system incorporates
tet regulatable elements so that expression of a gene can be switched
off and then on again so that its role in tumour initiation and
progression can be studied in detail [297].
Clearly the most powerful approach for validating loss of function
mutations is to use conditional loss of function alleles in the mouse.
Generating conditional alleles in mice is certainly not a high-
throughput strategy, since it takes at least a year to generate an allele
and to obtain the mice for study. There are, however, extensive
programmes such as the Knockout Mouse Programme (KOMP) and
the European Conditional Mutant Mouse (EUCOMM) Programme that
are generating impressive collections of conditional alleles in ES cells
and mice [303,304].
5. Concluding remarks
The study of human and mouse cancers has enabled us to get a
window on the genetic complexity of the cancer genome. As we go
forward, whole cancer genome sequencing is likely to move to the
fore as the primary approach applied to cancer genome analysis.
While it is likely that this approach will reveal a number of
frequently mutated genes that have been missed by other techni-
ques, intuitively it is likely that many genes will be uncovered that
are occasionally mutated. Additionally, it is likely that many
frequently rearranged regions containing numerous genes will be
identiﬁed, further complicating the identiﬁcation of those mutations
that drive the tumorigenic process. Deconvoluting this complexity
should be enabled by cross-species cancer gene analysis, which, as
described above, has already been shown to be a potent approach for
cancer gene identiﬁcation and validation. The limiting factor of the
cross-species cancer gene approach has been generating animal
models that faithfully recapitulate the human disease although
considerable efforts, such as the Mouse Models of Human Cancer
Consortium (MMHCC), are being made to redress this limitation.
Clearly, mice, in addition to other animal models, will play a major
role in furthering our understanding of the cancer genome. Large-
scale oncogenomic approaches that incorporate data from both
mouse and human and that apply in vivo techniques, such as shRNA
knockdown and viral mediated overexpression, to validate candidate
cancer genes are likely to become commonplace in the cancer
research arena [305].
What is certainly clear is that when we look back on this era in
cancer research we will realise how little we understood about the
genes and pathways associated with cancer formation and the
ingenuity of cancers to evolve and overcome all thatwe throwat them.
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